FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must ...
Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading ...
BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) ...
A team of researchers has developed a new gene-based technology that offers rapid, highly sensitive detection of multi-dru ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback